Biomarker

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, April 5, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Telephone, Patient, Defendant, City University, Journal, Biomarker, News, Scientific misconduct, Complaint, P.C, Neurobiology of Aging, Cognition, Safety, Data management, FDA, Pharmaceutical industry

Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Retrieved on: 
Wednesday, April 3, 2024
Cardiovascular disease, Patient, SAN, Biomarker, Bristol Myers Squibb, Protein, Proteomics, Science, Pulmonary fibrosis, Clinical trial, HCM, Heart, Hypertrophic cardiomyopathy, Translational medicine, Pharmaceutical industry

The SomaScan Platform is a high-throughput proteomics technology that presents a vast data landscape for researchers to explore by providing a comprehensive analysis of proteomic biomarkers.

Key Points: 
  • The SomaScan Platform is a high-throughput proteomics technology that presents a vast data landscape for researchers to explore by providing a comprehensive analysis of proteomic biomarkers.
  • These proteins enable a dynamic view into how patients respond to drugs, giving researchers insight into a drug’s success while minimizing invasive testing.
  • Bristol Myers Squibb has been an early adopter of the protein-based SomaScan Platform in immunology, cardiovascular disease and pulmonary fibrosis.
  • “Bristol Myers Squibb is a valued partner, and we are pleased to be collaborating on the development of these new tools that will accelerate insights into disease response,” says Michael Egholm, President and Chief Executive Officer of Standard BioTools™.

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Wednesday, April 3, 2024
Proton, Magnetic resonance imaging, SAN, Biomarker, MASH, MBA, Doctor of Philosophy, Therapy, Safety, Liver, Magnetic resonance, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • “Dosing the first subjects in our Phase 2a HERALD study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “We are pleased by the engagement of the clinicians and subjects, demonstrating the need for additional oral MASH therapies.
  • Topline safety and efficacy data from this study are expected in Q4 2024.

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Retrieved on: 
Wednesday, April 3, 2024
Patient, Growth, Conference, Biomarker, Prostate cancer, HERE, PSMA, Cancer

Dr. Dritschilo’s presentation will be on Thursday, April 4, 2024 at 3:10pm ET.

Key Points: 
  • Dr. Dritschilo’s presentation will be on Thursday, April 4, 2024 at 3:10pm ET.
  • A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE .
  • If attendees are not able to join the event live on the day of the Conference, an archived webcast will also be made available on www.EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference .
  • To request a virtual one-on-one meeting with Dr. Dritschilo and the Company’s management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at [email protected] .

EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Health, Partnership, Patient, Biomarker, Constipation, GMP, Safety, IBS, Therapy, Pharmaceutical industry

The Phase 2 study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol 60 patients with IBS and constipation across sites in the United Kingdom.

Key Points: 
  • The Phase 2 study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol 60 patients with IBS and constipation across sites in the United Kingdom.
  • The primary objective of the study is to assess the safety and tolerability of EBX-102-02.
  • Secondary and exploratory endpoints relate to assessing preliminary signals of efficacy of EBX-102-02 and potential biomarkers over a six-week period.
  • The trial will be delivered in partnership with the Functional Gut Clinic, a leading IBS diagnosis and treatment centre.

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
Wednesday, April 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.